Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine care. ESMO Real World Data and Digital Oncology.

L. Sellmann, D. Marschner, U.M. Martens, J. Schröder, T. Decker, M. Schuler, A. Schneeweiss, M. Reiser, M.K. Schuler, C. Vannier, M. Looß, S.M. Woerner, S. Grebhardt, P.R. Wright, S. Dille, B. Kasenda, S. Busies, K. Potthoff.

ESMO Real World Data and Digital Oncology. Volume 11, 2026, 100667, ISSN 2949-8201.

Abstract

Indikation: Präzisionsonkologie, Precision Oncology / Veranstaltung: - / Journal: ESMO Real World Data and Digital Oncology
INFINITY
2026
Institutionelle Variabilität in der Testung auf therapierelevante Treibermutationen bei Patienten mit NSCLC im Stadium IIIB/C oder IV: Real-World Daten aus dem prospektiven, multizentrischen CRISP-Register (AIO-TRK-0315)

Althoff, Friederike C., Hummel, H.-D., Kokowski, K., Elender, C., Grah, C., Jänicke, M., Fleitz, A., Zacharias, S., Groth, A., Ludwig, P., Nusch, A., Marcel, R., Pelz, H., Wiegand, J., Griesinger, F., Thomas, M., Eberhardt, W., Sebastian, M., DGHO 2025.

Oncol Res Treat 2025;48 (suppl 2):199

Poster

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2025
Real-world data on systemic treatment and biomarker testing in patients with advanced or metastatic endometrial cancer: results from the German registry platform SMARAGD

Juhasz-Böss I., Decker T., Zaiss M., Flade F., Beurer B, Jaenicke M., Winter S., Georganoudis N., Marschner N., Stickeler E., Welt A., Watermann D., Wöckel A., Gratzke K., , 2025,

International Journal of Gynecological Cancer, Volume 35, Issue 2, Supplement 1, 2025,100692, ISSN 1048-891X, https://doi.org/10.1016/j.ijgc.2024.100692.

Poster

Indikation: Endometrial Cancer, Endometriumkarzinom / Veranstaltung: ESGO / Journal: International Journal of Gynecological Cancer
SMARAGD
2025
Differences in health-related Quality of Life in patients with or without progression on palbociclib therapy. Preliminary results from the Non-Interventional Study PERFORM

Bjelic-Radisic, V; Korell, M; Pfeiler, G; Gabrysiak, T; Petersen, V; Deryal, M; Fietz, T; Radosa, J C; Decker, T; Schöttker, B; Knoblich, J; Rhein, U; Wegenast, A; Glastetter, E; Cordova, M; Zanucco, E; Glasstetter, M; Oppermann, U; Bartsch, R; Lux, M P

Senologie 2025; 22(02): 3 – 4

Poster

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal: Senologie
PERFORM
2025
Real-world effectiveness of palbociclib + endocrine therapy in tumor histological subgroups of patients with HR+/HER2- Advanced Breast Cancer: Interim Results of the PERFORM study.

R. Bartsch, M. Korell, G. Pfeiler, T. Gabrysiak, V. Petersen, M. Deryal, T.J. Fietz, J.C. Radosa, T. Decker, B. Schöttker, J. Knoblich, U. Rhein, N. Deuerling, M. Glasstetter, K. Gratzke, A. Wegenast, E. Glastetter, S. Sener, J. Dzieran, M.P. Lux.

Annals of Oncology, Volume 36, Supplement 2, 2025, Page S394, ISSN 0923-7534, https://doi.org/10.1016/j.annonc.2025.08.942

Poster

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
PERFORM
2025
Extended adjuvant (adj) neratinib in HER2+/HR+ early breast cancer (eBC) in clinical routine – interim analysis of the multinational, prospective, non-interventional study (NIS) ELEANOR

U. Breitenstein, D. Wrobel, D. Guth, M. Zaiss, J. Terhaag, M.-O. Zahn, L. Perlova-Griff, A. Distelrath, R. Würstlein, K. Apel, N. Deuerling, C. Vannier, R. Bartsch, C. Jackisch, V. Müller, M. Schmidt, M. Balic, G. Rinnerthaler, D. Lüftner, K. Zaman, M. Schwitter, N Harbeck.

The Breast, Volume 80, Supplement, 2025, 103911, https://doi.org/10.1016/j.breast.2025.103911

Poster

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: St. Gallen IBCC / Journal: The Breast
ELEANOR
2025
Comparison of treatment sequences in advanced pancreatic cancer

Marschner N, Haug N, Hegewisch-Becker S, Reiser M, Dörfel S, Liersch R, Linde H, Wolf T, Hof A, Kaiser-Osterhues A, Potthoff K, Jänicke M.

46th annual conference of the International Society for Clinical Biostatistics; 24-28 August 2025; Basel, Switzerland, p 555. Available from: https://iscb2025.info/data/ISCB46_Conference_Book.pdf

Abstract

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: ISCB / Journal:
TPK
2025
Extended adjuvant neratinib in HER2+/HR+ early breast cancer in clinical routine: Final results from the multi-national, prospective, observational study ELEANOR.

D.I. Lüftner, R. Bartsch, U. Breitenstein, C. Jackisch, V. Mueller, M. Schmidt, M. Balic, G. Rinnerthaler, K. Zaman, M. Schwitter, D. Wrobel, D. Guth, M. Zaiss, J. Terhaag, L. Perlova-Griff, R. Wuerstlein, T. Schinköthe, C. Vannier, N. Harbeck.

Annals of Oncology, Volume 36, Supplement 2, 2025, Pages S326-S327, https://doi.org/10.1016/j.annonc.2025.08.728.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
ELEANOR
2025
Extendierte Adjuvanz mit Neratinib bei HER2+/HR+ frühem Mammakarzinom in der klinischen Routine – finale Ergebnisse der multi-nationalen, prospektiven Beobachtungsstudie ELEANOR.

Zaman, K., Lüftner, D., Harbeck, N., Breitenstein, U., Jackisch, C., Müller, V., Schmidt, M., Balic, M., Rinnerthaler, G., Schwitter, M., Wrobel, D., Guth, D., Zaiss, M., Terhaag, J., Perlova-Griff, L., Distelrath, A., Deuerling, N., Würstlein, R., Schinköthe, T., Vannier, C., Bartsch, R.

Oncol Res Treat. 2025;48(suppl.2):286 (P1179)

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
ELEANOR
2025
MYLENE: Patient and healthcare provider satisfaction with sc versus iv daratumumab administration in patients with newly diagnosed multiple myeloma in routine clinical practice in Germany.

von der Heyde E.v.d.H., Reiser M., Baumgartner V., Englisch C., Frank O., Buchholz S., Kreimendahl F., Uhlig J., Bürkle D., Knauf W.

Oncol Res Treat 2025;48(suppl 2):208.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
MYLENE
2025